A hydrogel platform for co‐delivery of immunomodulatory proteins for pancreatic islet allografts

Abstract

Type 1 diabetes (T1D), an autoimmune disorder in which the insulin-producing β-cells in the islets of Langerhans in the pancreas are destroyed, afflicts over 1.6 million Americans. Although pancreatic islet transplantation has shown promise in treating

Injectable Granular Hydrogels Enable Avidity-Controlled Biotherapeutic Delivery

“…The sustained local delivery of therapeutics is often desirable and may be accomplished through the use of specific supramolecular interactions between a material scaffold and small molecule ,, or biomolecular ,, cargo. Here, we specifically leverage the GH interaction between Ad and CD, where avidity of the guest-modified protein (controlled by the number of conjugated guests) controls release.…”

Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment

“…Although indefinite allograft function was not achieved, the study successfully demonstrates a robust biomaterial-based method for delivering bioactive immunomodulatory proteins, extending their presence to a specific site ( Fig. 3 C) [ 74 ]. This approach holds promise for treating autoimmune diseases and facilitating organ transplantation in localized areas.…”

“…To maximize the effectiveness of Treg immunotherapy, it is imperative that these cells successfully migrate to specific target tissues, maintain stability within local organs, enhance their suppressive capabilities, and ensure their continued survival while fulfilling their intended functions [ 194 , 195 ]. In pursuit of these objectives, the use of biomaterials emerges as a compelling and supportive strategy for augmenting Treg immunotherapy and addressing these formidable challenges [ 73 , 74 , 76 , 78 , 81 , 83 , 84 , 91 , 96 , 108 ]. As a result, the prospect of employing biomaterial-enhanced Treg immunotherapy holds tremendous promise as a treatment option for patients undergoing organ transplants and those grappling with autoimmune diseases in the near future.…”

“…In this regard, biomedical engineers have developed various approaches to strengthen and/or attenuate the immune system using biomaterials in vitro or in vivo [ 7 , 8 ]. These approaches include delivering antigens to DCs [ 70 ], macrophage polarization [ 71 ], provoking T lymphocyte cell responses [ 72 ], inducing tolerogenic DCs [ 73 ] and Tregs [ 74 ], controlled-release of cytokines [ 75 ], immune-regulating camouflage [ 76 ], adoptive immune cell therapies [ 77 ], and tracking various immune cells [ 78 ]. Several studies have been conducted to improve the efficacy of immunotherapies for cancer and infections using biomaterials.…”

Enhancing Pancreatic B-Cell Viability and Longevity Through Novel Microencapsulation Strategies and Stromal Cell Support

“…Medina et al [153] developed a hydrogel platform for co-delivering an analog of IL-2, i.e. IL-2D, and FasL to achieve localized immunotolerance to pancreatic islets.…”